<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><title>News on Avandia</title><link href="http://diabetesinfoandtreatment.com/topic/avandia" rel="alternate"></link><id>http://diabetesinfoandtreatment.com/topic/avandia</id><updated>2010-11-30T13:48:56Z</updated><entry><title>Understanding Diabetes Insipidus</title><link href="http://diabetesinfoandtreatment.com/diabetes/understanding-diabetes-insipidus-4414490a" rel="alternate"></link><updated>2010-11-29T14:38:38Z</updated><author><name>EverydayHealth.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/diabetes/understanding-diabetes-insipidus-4414490a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Vascular Disorders"></category><category term="High Blood Pressure"></category><category term="Family Medicine"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Diabetes Symptoms"></category><category term="Type 1 Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Health Information Technology"></category><category term="American Academy of Family Physicians"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category><category term="Telemedicine"></category></entry><entry><title>Despite FDA Warning, Avandia Use Varies Across&amp;nbsp;U.S.</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-warning-avandia-varies-acrossnbspus-4423333a" rel="alternate"></link><updated>2010-11-29T14:42:23Z</updated><author><name>Health.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/diabetes/fda-warning-avandia-varies-acrossnbspus-4423333a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Oklahoma"></category><category term="Medicaid"></category><category term="North Dakota"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Mayo Foundation for Medical Education and Research"></category><category term="The New England Journal of Medicine"></category><category term="Rochester"></category><category term="American Diabetes Association"></category><category term="University of Miami Leonard M. Miller School of Medicine"></category><category term="Avandia"></category><category term="Nilay Shah"></category><category term="Luigi Meneghini"></category></entry><entry><title>Despite FDA Warning, Avandia Use Varies Across U.S.</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-warning-avandia-varies-4405197a" rel="alternate"></link><updated>2010-11-29T14:35:08Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/diabetes/fda-warning-avandia-varies-4405197a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Oklahoma"></category><category term="Medicaid"></category><category term="North Dakota"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Mayo Foundation for Medical Education and Research"></category><category term="The New England Journal of Medicine"></category><category term="Rochester"></category><category term="American Diabetes Association"></category><category term="University of Miami Leonard M. Miller School of Medicine"></category><category term="Avandia"></category><category term="Nilay Shah"></category><category term="Luigi Meneghini"></category></entry><entry><title>Diabetes Research Made Significant Strides in Past Year</title><link href="http://diabetesinfoandtreatment.com/type-1-diabetes/diabetes-research-significant-strides-year-4423501a" rel="alternate"></link><updated>2010-11-29T14:42:27Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/type-1-diabetes/diabetes-research-significant-strides-year-4423501a/</id><summary type="html">...</summary><category term="Weight Loss"></category><category term="Contagious and Infectious Diseases"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 1 Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Vaccines"></category><category term="United States"></category><category term="New York City"></category><category term="Food and Drug Administration"></category><category term="Centers for Disease Control and Prevention"></category><category term="GlaxoSmithKline plc"></category><category term="World Health Organization"></category><category term="American Diabetes Association"></category><category term="Juvenile Diabetes Research Foundation"></category><category term="United Nations"></category><category term="International Diabetes Federation"></category><category term="Avandia"></category><category term="Montefiore Medical Center"></category><category term="University of Calgary"></category><category term="Sue Kirkman"></category><category term="Richard Insel"></category><category term="Body Weight"></category><category term="Pere Santamaria"></category><category term="Immunotherapy"></category><category term="Joel Zonszein"></category><category term="Clinical Diabetes Center"></category><category term="University of Geneva Medical School"></category><category term="Pedro Herrera"></category></entry><entry><title>Rosiglitazone</title><link href="http://diabetesinfoandtreatment.com/diabetes/rosiglitazone-4692080a" rel="alternate"></link><updated>2010-11-30T13:48:56Z</updated><author><name>Mahalo</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-30:/diabetes/rosiglitazone-4692080a/</id><summary type="html">...</summary><category term="Eyesight and Eye Health"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Nyha Iii"></category></entry><entry><title>Concerns about the safety of Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/concerns-safety-avandia-4506787a" rel="alternate"></link><updated>2010-11-29T15:18:53Z</updated><author><name>Helium</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/diabetes/concerns-safety-avandia-4506787a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="David Graham"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Causes for increase in coronary artery disease in women </title><link href="http://diabetesinfoandtreatment.com/diabetes/increase-coronary-artery-disease-women-4506842a" rel="alternate"></link><updated>2010-11-29T15:18:54Z</updated><author><name>Helium</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/diabetes/increase-coronary-artery-disease-women-4506842a/</id><summary type="html">...</summary><category term="Cholesterol"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Crestor"></category><category term="Zetia"></category><category term="Avandia"></category><category term="Plavix"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-4654121a" rel="alternate"></link><updated>2010-11-30T13:08:55Z</updated><author><name>Mahalo</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-30:/diabetes/avandia-4654121a/</id><summary type="html">...</summary><category term="Exercise and Fitness"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Avandia"></category></entry><entry><title>Side effects of Avandia</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/side-effects-avandia-4511390a" rel="alternate"></link><updated>2010-11-29T15:20:56Z</updated><author><name>Helium</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-29:/type-2-diabetes/side-effects-avandia-4511390a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Diabetes Symptoms"></category><category term="Hypoglycemia"></category><category term="Prediabetes"></category><category term="Type 2 Diabetes"></category><category term="Avandia"></category></entry><entry><title>Avandia Coupons</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-coupons-4637526a" rel="alternate"></link><updated>2010-11-30T12:52:45Z</updated><author><name>Mahalo</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-30:/diabetes/avandia-coupons-4637526a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category></entry><entry><title>Federal prosecutors probing Glaxo diabetes pill</title><link href="http://diabetesinfoandtreatment.com/diabetes/federal-prosecutors-probing-glaxo-diabetes-pill-2482151a" rel="alternate"></link><updated>2010-10-21T15:00:48Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-21:/diabetes/federal-prosecutors-probing-glaxo-diabetes-pill-2482151a/</id><summary type="html">&lt;div id="subtitle"&gt;Feds issue subpoena over &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;Glaxo&lt;/a&gt;'s diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, a month after FDA restricts its use&lt;/div&gt;&lt;div&gt;&lt;p&gt;British drug maker GlaxoSmithKline reported Thursday that its controversial diabetes drug Avandia is under investigation by federal and state law enforcement officials in the &lt;span&gt;U.S.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The announcement came less than a month after the &lt;span&gt;&lt;a ti...</summary><category term="Law"></category><category term="Personal Injury Law"></category><category term="Trials"></category><category term="Civil Trials"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Andrew Witty"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>diabetes drug</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-drug-3851805a" rel="alternate"></link><updated>2010-11-02T21:22:17Z</updated><author><name>hubPage</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/diabetes-drug-3851805a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>www.Avandia.Com - The Avandia Website - Avandia Diabetes</title><link href="http://diabetesinfoandtreatment.com/diabetes/wwwavandiacom-avandia-website-avandia-diabetes-3861695a" rel="alternate"></link><updated>2010-11-02T21:39:18Z</updated><author><name>hubPage</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/wwwavandiacom-avandia-website-avandia-diabetes-3861695a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Avandia"></category></entry><entry><title>Diabities &amp; Drugs - See Video.</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/diabities-drugs-video-3764400a" rel="alternate"></link><updated>2010-11-02T18:49:45Z</updated><author><name>hubPage</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/type-2-diabetes/diabities-drugs-video-3764400a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="India"></category><category term="Asia"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Glucophage"></category><category term="South Asia"></category><category term="Daonil"></category><category term="Micronase"></category></entry><entry><title>FDA restricts access to Avandia, cites increased cardiovascular risks</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-restricts-access-avandia-cites-increased-cardiovascular-risks-1736042a" rel="alternate"></link><updated>2010-10-06T20:22:29Z</updated><author><name>Modern Medicine</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-06:/diabetes/fda-restricts-access-avandia-cites-increased-cardiovascular-risks-1736042a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Health Care Services Sector"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Margaret Hamburg"></category></entry><entry><title>FDA Restricts Access to Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-restricts-access-avandia-1601082a" rel="alternate"></link><updated>2010-10-03T05:06:00Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-03:/diabetes/fda-restricts-access-avandia-1601082a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Center for Drug Evaluation and Research"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="University of Miami Leonard M. Miller School of Medicine"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Hamburg"></category><category term="Margaret Hamburg"></category><category term="Cardiovascular Medicine"></category><category term="Ellen Strahlman"></category><category term="Ronald Goldberg"></category><category term="Janet Woodock"></category></entry><entry><title>Protecting Health By Reducing Options</title><link href="http://diabetesinfoandtreatment.com/diabetes/protecting-health-reducing-options-3505953a" rel="alternate"></link><updated>2010-11-02T12:27:28Z</updated><author><name>Forbes</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/protecting-health-reducing-options-3505953a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="European Union"></category><category term="Food and Drug Administration"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Margaret Hamburg"></category><category term="Joshua Sharfstein"></category><category term="Steven Nissen"></category><category term="Kathy Wolski"></category></entry><entry><title>Saved By The Power of REMS</title><link href="http://diabetesinfoandtreatment.com/diabetes/saved-power-rems-3505955a" rel="alternate"></link><updated>2010-11-02T12:27:28Z</updated><author><name>Forbes</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/saved-power-rems-3505955a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="Steven Nissen"></category><category term="Ruth Day"></category></entry><entry><title>Time to Review Your Medications</title><link href="http://diabetesinfoandtreatment.com/diabetes/time-review-medications-3526557a" rel="alternate"></link><updated>2010-11-02T12:53:55Z</updated><author><name>Beliefnet</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/time-review-medications-3526557a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="The New York Times Company"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="The New England Journal of Medicine"></category><category term="Avandia"></category><category term="American Food and Drug Administration"></category><category term="Steven Nissen"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Diet and Exercise Trump Diabetes Drugs</title><link href="http://diabetesinfoandtreatment.com/diabetes/diet-exercise-trump-diabetes-drugs-1571902a" rel="alternate"></link><updated>2010-09-27T15:04:09Z</updated><author><name>LiveScience</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-27:/diabetes/diet-exercise-trump-diabetes-drugs-1571902a/</id><summary type="html">...</summary><category term="Diet and Nutrition"></category><category term="Weight Loss"></category><category term="Cancer"></category><category term="Bladder Cancer"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Diabetic Diets"></category><category term="Kidney and Urologic Health"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="The New England Journal of Medicine"></category><category term="Agency for Healthcare Research and Quality"></category><category term="Avandia"></category><category term="Actos"></category><category term="Cardiovascular Medicine"></category><category term="Body Weight"></category></entry><entry><title>GSK's Diabetes Pill: Lessons Learned, Unanswered Questions</title><link href="http://diabetesinfoandtreatment.com/diabetes/gsks-diabetes-pill-lessons-learned-unanswered-questions-1567016a" rel="alternate"></link><updated>2010-09-26T03:00:49Z</updated><author><name>SeekingAlpha</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-26:/diabetes/gsks-diabetes-pill-lessons-learned-unanswered-questions-1567016a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="New York State Office of the Attorney General"></category><category term="Europe"></category><category term="Yale University"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Paxil"></category><category term="Bristol-Myers Squibb Company"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Eliot Spitzer"></category><category term="Steve Nissen"></category><category term="Harlan Krumholz"></category><category term="Cardiovascular Medicine"></category><category term="Patient-Centered Outcomes Research Institute"></category></entry><entry><title>Avandia (rosiglitazone): REMS - Risk of Cardiovascular Events</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-rosiglitazone-rems-risk-cardiovascular-events-3516410a" rel="alternate"></link><updated>2010-11-02T12:40:18Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/avandia-rosiglitazone-rems-risk-cardiovascular-events-3516410a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Food and Drug Administration"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Avandia's Exception</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandias-exception-1561019a" rel="alternate"></link><updated>2010-09-23T21:03:34Z</updated><author><name>Forbes</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/avandias-exception-1561019a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="University of Chicago Law School"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Actos"></category><category term="Twitter Inc."></category><category term="Forbes Media LLC"></category><category term="Cardiovascular Medicine"></category><category term="Anup Malani"></category><category term="University of Chicago Pritzker School of Medicine"></category><category term="Rebecca Killion"></category></entry><entry><title>Diabetes drug Avandia banned in Europe, restricted in US</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-drug-avandia-banned-europe-restricted-1560023a" rel="alternate"></link><updated>2010-09-23T14:15:51Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/diabetes-drug-avandia-banned-europe-restricted-1560023a/</id><summary type="html">&lt;div&gt;&lt;p&gt;The diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; will no longer be available to patients in &lt;a title="Europe" href="/topic/Europe" &gt;Europe&lt;/a&gt; and will be restricted in the US over fears it increases the risk of heart attack and strokes, regulators said Thursday.&lt;/p&gt;&lt;p&gt;The controversial drug made by British company &lt;span&gt;&lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;&lt;/span&gt; would be pulled in Europe within the next few months,...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Avandamet"></category><category term="Margaret Hamburg"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Summary Box: US, Europe restrict Avandia use</title><link href="http://diabetesinfoandtreatment.com/diabetes/summary-box-europe-restrict-avandia-1559805a" rel="alternate"></link><updated>2010-09-23T13:30:33Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/summary-box-europe-restrict-avandia-1559805a/</id><summary type="html">&lt;div id="subtitle"&gt;Summary Box: &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;FDA&lt;/a&gt; leaves diabetes pill on market with restrictions, Europeans ban sales&lt;/div&gt;&lt;div&gt;&lt;p&gt;SPLIT DECISION: &lt;a title="United States" href="/topic/United+States" &gt;U.S.&lt;/a&gt; health officials restricted access to the controversial diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; Thursday, even as European regulators ordered it off the market based on heart attack risk...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>FDA Restricts Use of Diabetes Drug Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-restricts-diabetes-drug-avandia-1560158a" rel="alternate"></link><updated>2010-09-23T15:04:07Z</updated><author><name>WebMD</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/fda-restricts-diabetes-drug-avandia-1560158a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Sciences"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Actos"></category><category term="Hamburg"></category><category term="Margaret Hamburg"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>US limits Avandia diabetes drug use, falls short of ban</title><link href="http://diabetesinfoandtreatment.com/diabetes/limits-avandia-diabetes-drug-falls-short-ban-1558924a" rel="alternate"></link><updated>2010-09-23T10:15:25Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/limits-avandia-diabetes-drug-falls-short-ban-1558924a/</id><summary type="html">&lt;div&gt;&lt;p&gt;The top US food regulator Thursday severely restricted the use of the controversial diabetes drug, &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, made by British firm &lt;span&gt;&lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;&lt;/span&gt;, but stopped short of an outright ban.&lt;/p&gt;&lt;p&gt;The &lt;span&gt;&lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;Food and Drug Administration&lt;/a&gt;&lt;/span&gt; said in a statement it was taking the s...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="United States"></category><category term="European Union"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Margaret Hamburg"></category></entry><entry><title>US restricts, EU bans controversial diabetes pill</title><link href="http://diabetesinfoandtreatment.com/diabetes/restricts-eu-bans-controversial-diabetes-pill-1559870a" rel="alternate"></link><updated>2010-09-23T13:56:04Z</updated><author><name>Investors Business Daily</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/restricts-eu-bans-controversial-diabetes-pill-1559870a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="United States"></category><category term="Washington, DC"></category><category term="New Jersey"></category><category term="Trenton"></category><category term="Japan"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Yale University"></category><category term="European Commission"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="Actos"></category><category term="East Asia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Hamburg"></category><category term="Margaret Hamburg"></category><category term="Medical Lauran Neergaard"></category><category term="Linda Johnson"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Steve Nissen"></category><category term="England"></category><category term="Harlan Krumholz"></category><category term="Medical Maria Cheng"></category><category term="Cardiovascular Medicine"></category><category term="London (England)"></category><category term="Hans-Georg Eichler"></category><category term="Paul Thacker"></category></entry><entry><title>European agency says Avandia should be pulled</title><link href="http://diabetesinfoandtreatment.com/diabetes/european-agency-avandia-pulled-1558873a" rel="alternate"></link><updated>2010-09-23T09:16:50Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/european-agency-avandia-pulled-1558873a/</id><summary type="html">&lt;div id="subtitle"&gt;&lt;a title="European Medicines Agency" href="/topic/European+Medicines+Agency" &gt;European Medicines Agency&lt;/a&gt; says diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; should be pulled from market&lt;/div&gt;&lt;div&gt;&lt;p&gt;European Medicines Agency says diabetes drug Avandia should be pulled from market.&lt;/p&gt;&lt;p&gt;In a news briefing on Thursday, the agency said it would suspend its marketing authorizations for the controversial drug which is linked to heart attacks.&lt;/p&gt;&lt;p&gt;It said ...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="Avandia"></category></entry><entry><title>FDA keeps diabetes pill with heart risks on market</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-diabetes-pill-heart-risks-market-1558503a" rel="alternate"></link><updated>2010-09-23T08:30:30Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/fda-diabetes-pill-heart-risks-market-1558503a/</id><summary type="html">&lt;div id="subtitle"&gt;FDA leaves diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; on market but restricts access due to heart attack risks&lt;/div&gt;&lt;div&gt;&lt;p&gt;Federal health regulators will allow &lt;span&gt;&lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;&lt;/span&gt; to continue selling a controversial diabetes pill but will restrict access to the once-blockbuster drug because of heart attack risks.&lt;/p&gt;&lt;p&gt;The &lt;span&gt;&lt;a title="Food and Drug Administration" href=...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>FDA significantly restricts access to the diabetes drug Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-significantly-restricts-access-diabetes-drug-avandia-1559601a" rel="alternate"></link><updated>2010-09-23T12:38:36Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/fda-significantly-restricts-access-diabetes-drug-avandia-1559601a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Food and Drug Administration"></category><category term="Rockville"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Margaret Hamburg"></category><category term="Karen Riley"></category></entry><entry><title>FDA restricts use of risky diabetes drug Avandia. What are safer options?</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-restricts-risky-diabetes-drug-avandia-safer-options-1559011a" rel="alternate"></link><updated>2010-09-23T11:03:19Z</updated><author><name>Consumer Reports</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/fda-restricts-risky-diabetes-drug-avandia-safer-options-1559011a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Stroke"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Best Buy Co. Inc."></category><category term="John Santa"></category><category term="Consumer Reports Health Ratings Center"></category><category term="Cardiovascular Medicine"></category><category term="Brain and Nerve Health"></category></entry><entry><title>It&amp;#8217;s a Split Decision for Avandia: U.S. Says Yes, Europe Says Non</title><link href="http://diabetesinfoandtreatment.com/diabetes/it238217s-split-decision-avandia-europe-1559286a" rel="alternate"></link><updated>2010-09-23T11:12:17Z</updated><author><name>Wall Street Journal Health Blog</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-23:/diabetes/it238217s-split-decision-avandia-europe-1559286a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Actos"></category><category term="Avandamet"></category><category term="Avandaryl"></category><category term="Dow Jones &amp; Co. Inc."></category><category term="Ellen Strahlman"></category></entry><entry><title>What Are Thiazolidinediones?</title><link href="http://diabetesinfoandtreatment.com/diabetes/thiazolidinediones-4325258a" rel="alternate"></link><updated>2010-11-05T10:07:41Z</updated><author><name>WiseGeek</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-05:/diabetes/thiazolidinediones-4325258a/</id><summary type="html">...</summary><category term="Cholesterol"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Food and Drug Administration"></category><category term="Women's Health"></category><category term="Avandia"></category><category term="Actos"></category><category term="Rezulin"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>UK Drug Regulators Want Avandia Pulled From Market</title><link href="http://diabetesinfoandtreatment.com/diabetes/uk-drug-regulators-avandia-pulled-market-1372019a" rel="alternate"></link><updated>2010-09-11T13:32:59Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-11:/diabetes/uk-drug-regulators-avandia-pulled-market-1372019a/</id><summary type="html">...</summary><category term="Media"></category><category term="Magazines"></category><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Sciences"></category><category term="Life Sciences"></category><category term="Medical Science"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="BMJ Publishing Group Ltd."></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category><category term="London (England)"></category></entry><entry><title>U.K. Regulator Says GSK's Diabetes Drug Should Go</title><link href="http://diabetesinfoandtreatment.com/diabetes/uk-regulator-gsks-diabetes-drug-1380994a" rel="alternate"></link><updated>2010-09-11T19:11:21Z</updated><author><name>SeekingAlpha</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-11:/diabetes/uk-regulator-gsks-diabetes-drug-1380994a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="British Broadcasting Corporation"></category><category term="Reuters Group plc"></category><category term="Fiona Godlee"></category><category term="Edwin Gale"></category></entry><entry><title>UK Regulator Says GSK's Diabetes Drug Should Go</title><link href="http://diabetesinfoandtreatment.com/diabetes/uk-regulator-gsks-diabetes-drug-1380981a" rel="alternate"></link><updated>2010-09-11T19:10:40Z</updated><author><name>SeekingAlpha</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-11:/diabetes/uk-regulator-gsks-diabetes-drug-1380981a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="British Broadcasting Corporation"></category><category term="Reuters Group plc"></category><category term="Fiona Godlee"></category><category term="Edwin Gale"></category><category term="UK's Commission on Human Medicines"></category></entry><entry><title>UK regulators want Avandia diabetes pill pulled</title><link href="http://diabetesinfoandtreatment.com/diabetes/uk-regulators-avandia-diabetes-pill-pulled-1040075a" rel="alternate"></link><updated>2010-09-06T14:20:16Z</updated><author><name>AP Features</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-06:/diabetes/uk-regulators-avandia-diabetes-pill-pulled-1040075a/</id><summary type="html">&lt;div&gt;&lt;p&gt;&lt;span&gt;&lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;&lt;/span&gt;'s controversial diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; should be pulled from the U.K. market because of concerns that the drug can increase the risk of heart attacks, British drug regulators said Monday.&lt;/p&gt;&lt;p&gt;The Medicines and Healthcare products Regulatory Agency (MHRA) said an independent panel of experts had advised it that the risks of Avandia outweigh its ...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Western Europe"></category><category term="BMJ Publishing Group Ltd."></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Diabetes drug still prescribed months after heart attack fears</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-drug-prescribed-months-heart-attack-fears-1395727a" rel="alternate"></link><updated>2010-09-12T02:52:06Z</updated><author><name>ThisIsLondon.co.uk</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-12:/diabetes/diabetes-drug-prescribed-months-heart-attack-fears-1395727a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="United Kingdom"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="University College London"></category><category term="Western Europe"></category><category term="BMJ Publishing Group Ltd."></category><category term="Avandia"></category><category term="British Broadcasting Corporation"></category><category term="University of East Anglia"></category><category term="University of Birmingham"></category><category term="Cardiovascular Medicine"></category><category term="Deborah Cohen"></category><category term="Yoon Loke"></category></entry><entry><title>Safety fear drug 'still prescribed'</title><link href="http://diabetesinfoandtreatment.com/diabetes/safety-fear-drug-prescribed-1395696a" rel="alternate"></link><updated>2010-09-12T02:51:12Z</updated><author><name>ThisIsLondon.co.uk</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-12:/diabetes/safety-fear-drug-prescribed-1395696a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="United Kingdom"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="University College London"></category><category term="Western Europe"></category><category term="BMJ Publishing Group Ltd."></category><category term="Avandia"></category><category term="University of Birmingham"></category><category term="Cardiovascular Medicine"></category><category term="Deborah Cohen"></category><category term="John Yudkin"></category><category term="Nick Freemantle"></category><category term="Commission on Human Medicines"></category></entry><entry><title>Diabetes drug Avandia just as safe as Actos: study</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-drug-avandia-safe-actos-study-1028285a" rel="alternate"></link><updated>2010-08-24T14:30:13Z</updated><author><name>Reuters US Online Report Health News</name></author><id>tag:diabetesinfoandtreatment.com,2010-08-24:/diabetes/diabetes-drug-avandia-safe-actos-study-1028285a/</id><summary type="html">&lt;div&gt;&lt;p&gt;&lt;a title="Chicago" href="/topic/Chicago" &gt;CHICAGO&lt;/a&gt; (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; was no riskier to the heart than a rival, U.S. researchers said on Tuesday, a finding that contradicts earlier studies and adds new fodder to the roiling debate over the drug's safety.&lt;/p&gt;&lt;p&gt;The study of ...</summary><category term="Health Care Issues"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Insurance Industry"></category><category term="Insurance Carriers"></category><category term="Health and Medical Insurance Carriers"></category><category term="Health Care Plans"></category><category term="United States"></category><category term="Medicare"></category><category term="Chicago"></category><category term="Food and Drug Administration"></category><category term="Centers for Medicare &amp; Medicaid Services"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="Reuters Group plc"></category><category term="David Graham"></category><category term="WellPoint Inc."></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Paying for Health Care"></category><category term="Cardiovascular Medicine"></category><category term="Debra Wertz"></category></entry><entry><title>Avandia: Less Risky in Younger, Healthier Patients?</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-risky-younger-healthier-patients-1372678a" rel="alternate"></link><updated>2010-09-11T13:58:34Z</updated><author><name>WebMD</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-11:/diabetes/avandia-risky-younger-healthier-patients-1372678a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Geriatric Medicine"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medicare"></category><category term="Food and Drug Administration"></category><category term="The Cleveland Clinic"></category><category term="American Heart Association"></category><category term="Cleveland"></category><category term="WebMD Inc."></category><category term="Avandia"></category><category term="Actos"></category><category term="David Graham"></category><category term="Steven Nissen"></category><category term="Cardiovascular Medicine"></category><category term="Debra Wertz"></category><category term="Leanne Chrisman"></category></entry><entry><title>Another Twist in the Chronicles of Avandia!</title><link href="http://diabetesinfoandtreatment.com/diabetes/twist-chronicles-avandia-3592219a" rel="alternate"></link><updated>2010-11-02T14:14:45Z</updated><author><name>Wall Street Journal Health Blog</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/twist-chronicles-avandia-3592219a/</id><summary type="html">...</summary><category term="Media"></category><category term="Magazines"></category><category term="Company Activities and Information"></category><category term="Corporate Reporting"></category><category term="Earnings and Losses"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Iowa"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="The New England Journal of Medicine"></category><category term="Avandia"></category><category term="Rezulin"></category><category term="Time Inc."></category><category term="U.S. Senate Committee on Finance"></category><category term="Chuck Grassley"></category><category term="Josh Sharfstein"></category><category term="Cardiovascular Medicine"></category><category term="Kevin Colgan"></category><category term="Robert Misbin"></category></entry><entry><title>New Data Supports Link Between Diabetes Drugs, Fractures</title><link href="http://diabetesinfoandtreatment.com/diabetes/new-data-supports-link-diabetes-drugs-fractures-1335826a" rel="alternate"></link><updated>2010-09-10T20:14:45Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/new-data-supports-link-diabetes-drugs-fractures-1335826a/</id><summary type="html">...</summary><category term="Endocrinology"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Orthopedics"></category><category term="Injuries and Traumas"></category><category term="New York City"></category><category term="Food and Drug Administration"></category><category term="University of Michigan"></category><category term="State University of New York System"></category><category term="Avandia"></category><category term="Actos"></category><category term="University of Rochester Medical Center"></category><category term="Muscle and Skeletal Health"></category></entry><entry><title>Is Your Blood Sugar High?</title><link href="http://diabetesinfoandtreatment.com/diabetes-symptoms/blood-sugar-high-1328838a" rel="alternate"></link><updated>2010-09-10T17:44:29Z</updated><author><name>EverydayHealth.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes-symptoms/blood-sugar-high-1328838a/</id><summary type="html">...</summary><category term="Family"></category><category term="Parenting"></category><category term="Child Development"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Diabetes Symptoms"></category><category term="Medical Treatments and Procedures"></category><category term="Obesity"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Medical Diagnostic Products and Services"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Medical Imaging and Diagnostics"></category><category term="Body Weight"></category><category term="Puberty"></category></entry><entry><title>Diabetics Urged to Confer With Their Doctor About Avandia Use</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetics-urged-confer-doctor-avandia-1335717a" rel="alternate"></link><updated>2010-09-10T20:11:28Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/diabetics-urged-confer-doctor-avandia-1335717a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="New York City"></category><category term="Food and Drug Administration"></category><category term="Rochester"></category><category term="American Heart Association"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Actos"></category><category term="American Association of Clinical Endocrinologists"></category><category term="The Endocrine Society"></category><category term="University of Rochester Medical Center"></category><category term="Brooklyn Hospital Center"></category><category term="Cardiovascular Medicine"></category><category term="Arthur Moss"></category><category term="Jacob Warman"></category></entry><entry><title>FDA Panel Seems Skeptical Over Key Avandia Data</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-panel-skeptical-key-avandia-data-1335722a" rel="alternate"></link><updated>2010-09-10T20:11:39Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/fda-panel-skeptical-key-avandia-data-1335722a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="The New York Times Company"></category><category term="Food and Drug Administration"></category><category term="National Heart, Lung, and Blood Institute"></category><category term="GlaxoSmithKline plc"></category><category term="The New England Journal of Medicine"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Actos"></category><category term="American Association of Clinical Endocrinologists"></category><category term="The Endocrine Society"></category><category term="University of Newcastle upon Tyne"></category><category term="Cardiovascular Medicine"></category><category term="Ellis Unger"></category><category term="Thomas Marciniak"></category><category term="Ellen Strahlman"></category></entry><entry><title>Avandia's future murky after FDA panel vote</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandias-future-murky-fda-panel-vote-3519685a" rel="alternate"></link><updated>2010-11-02T12:43:42Z</updated><author><name>American Medical Association News</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/avandias-future-murky-fda-panel-vote-3519685a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Endocrinology"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="United States"></category><category term="Denver"></category><category term="Food and Drug Administration"></category><category term="Centers for Disease Control and Prevention"></category><category term="Gaithersburg"></category><category term="GlaxoSmithKline plc"></category><category term="The New England Journal of Medicine"></category><category term="American Heart Association"></category><category term="Journal of the American Medical Association"></category><category term="University of Colorado at Denver and Health Sciences Center"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Actos"></category><category term="The Endocrine Society"></category><category term="U.S. Senate Committee on Finance"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Robert Eckel"></category><category term="Alan Garber"></category><category term="Cardiovascular Medicine"></category><category term="Ellen Strahlman"></category></entry><entry><title>Planned Study of Avandia in Doubt After FDA Review</title><link href="http://diabetesinfoandtreatment.com/diabetes/planned-study-avandia-doubt-fda-review-3582261a" rel="alternate"></link><updated>2010-11-02T14:03:59Z</updated><author><name>Science</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/planned-study-avandia-doubt-fda-review-3582261a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Sciences"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="Avandia"></category><category term="Actos"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>US Agency Puts Hold On Much-Debated Avandia Study</title><link href="http://diabetesinfoandtreatment.com/diabetes/agency-puts-hold-muchdebated-avandia-study-3516103a" rel="alternate"></link><updated>2010-11-02T12:39:37Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/agency-puts-hold-muchdebated-avandia-study-3516103a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Japan"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="Actos"></category><category term="East Asia"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Steven Nissen"></category><category term="England"></category><category term="Cardiovascular Medicine"></category><category term="London (England)"></category></entry><entry><title>Study raises hope for safer diabetes drugs</title><link href="http://diabetesinfoandtreatment.com/diabetes/study-raises-hope-safer-diabetes-drugs-998234a" rel="alternate"></link><updated>2010-07-21T15:30:50Z</updated><author><name>Reuters US Online Report Health News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-21:/diabetes/study-raises-hope-safer-diabetes-drugs-998234a/</id><summary type="html">&lt;div&gt;&lt;p&gt;&lt;a title="Chicago" href="/topic/Chicago" &gt;CHICAGO&lt;/a&gt; (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - A new understanding of the link between diabetes and obesity may help drug companies design safer versions of treatments like &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, &lt;a title="United States" href="/topic/United+States" &gt;U.S.&lt;/a&gt; researchers said on Wednesda...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Prediabetes"></category><category term="Type 2 Diabetes"></category><category term="Obesity"></category><category term="Life Sciences"></category><category term="Biology"></category><category term="Genetics"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Chicago"></category><category term="California"></category><category term="Boston"></category><category term="Food and Drug Administration"></category><category term="Dana-Farber Cancer Institute"></category><category term="Nature Publishing Group"></category><category term="GlaxoSmithKline plc"></category><category term="The Scripps Research Institute"></category><category term="Avandia"></category><category term="Actos"></category><category term="Reuters Group plc"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category><category term="Body Weight"></category><category term="Bruce Spiegelman"></category></entry><entry><title>FDA issues hold on much-debated Avandia study</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-issues-hold-muchdebated-avandia-study-998003a" rel="alternate"></link><updated>2010-07-21T09:45:22Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-21:/diabetes/fda-issues-hold-muchdebated-avandia-study-998003a/</id><summary type="html">&lt;div id="subtitle"&gt;FDA bars new patients from enrolling in safety study of diabetes drug tied to heart risks&lt;/div&gt;&lt;div&gt;&lt;p&gt;Federal health officials say new patients should not be enrolled in a study of &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s controversial diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, after experts last week said the drug increases heart risks.&lt;/p&gt;&lt;p&gt;The &lt;a title="Food and Drug Administration" href="/topic/Food...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category></entry><entry><title>Diabetes Drug Shakedown Yields Unclear Decision from FDA Committee</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-drug-shakedown-yields-unclear-decision-fda-committee-1314931a" rel="alternate"></link><updated>2010-09-10T14:44:56Z</updated><author><name>Scientific American</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/diabetes-drug-shakedown-yields-unclear-decision-fda-committee-1314931a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="The New York Times Company"></category><category term="Washington, DC"></category><category term="Food and Drug Administration"></category><category term="National Institutes of Health"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="World Health Organization"></category><category term="The New England Journal of Medicine"></category><category term="American Heart Association"></category><category term="Toronto"></category><category term="Avandia"></category><category term="Actos"></category><category term="U.S. Senate Committee on Finance"></category><category term="Public Citizen Foundation"></category><category term="Sidney Wolfe"></category><category term="Steve Nissen"></category><category term="Sunnybrook and Women's College Health Sciences Centre"></category><category term="Cardiovascular Medicine"></category><category term="David Juurlink"></category></entry><entry><title>FDA Panel Math: How Avandia Vote is Being Played</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-panel-math-avandia-vote-played-3592055a" rel="alternate"></link><updated>2010-11-02T14:14:39Z</updated><author><name>Wall Street Journal Health Blog</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/fda-panel-math-avandia-vote-played-3592055a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="USA TODAY"></category><category term="Forbes Media LLC"></category><category term="The Washington Post Company"></category><category term="Los Angeles Times"></category><category term="Night of the Living Dead"></category></entry><entry><title>Experts urge US to restrict drug Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/experts-urge-restrict-drug-avandia-992172a" rel="alternate"></link><updated>2010-07-14T22:15:38Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-14:/diabetes/experts-urge-restrict-drug-avandia-992172a/</id><summary type="html">&lt;div&gt;&lt;p&gt;A majority of members of a key advisory committee recommended  that the &lt;a title="United States" href="/topic/United+States" &gt;US&lt;/a&gt; government allow diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; to stay on the market with greater restrictions on its sale.&lt;/p&gt;&lt;p&gt;Most of the panel's members agreed that the drug increases the risk of heart problems, but only 12 of the 33-member expert panel voted to remove &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+pl...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Philadelphia"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="Actos"></category><category term="U.S. Senate Committee on Finance"></category><category term="Chuck Grassley"></category><category term="Max Baucus"></category><category term="Karen Riley"></category><category term="Mary Anne Rhyne"></category><category term="Cardiovascular Medicine"></category><category term="Ellen Strahlman"></category></entry><entry><title>FDA Panel Votes to Restrict Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-panel-votes-restrict-avandia-1335639a" rel="alternate"></link><updated>2010-09-10T20:08:59Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/fda-panel-votes-restrict-avandia-1335639a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>GlaxoSmithKline Statement in Response to FDA Advisory Committees' Vote on Safety of Avandia (rosiglitazone)</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxosmithkline-statement-response-fda-advisory-committees-vote-safety-avandia-rosiglitazone-3515992a" rel="alternate"></link><updated>2010-11-02T12:39:31Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/glaxosmithkline-statement-response-fda-advisory-committees-vote-safety-avandia-rosiglitazone-3515992a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category><category term="Private Securities Litigation Reform Act"></category><category term="Ellen Strahlman"></category></entry><entry><title>How the FDA Panel&amp;#8217;s Votes on Avandia Votes Went Down</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-panel238217s-votes-avandia-votes-3592053a" rel="alternate"></link><updated>2010-11-02T14:14:39Z</updated><author><name>Wall Street Journal Health Blog</name></author><id>tag:diabetesinfoandtreatment.com,2010-11-02:/diabetes/fda-panel238217s-votes-avandia-votes-3592053a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="Forbes Media LLC"></category><category term="Dow Jones &amp; Co. Inc."></category></entry><entry><title>Glaxo's diabetes drug Avandia faces moment of truth</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxos-diabetes-drug-avandia-faces-moment-truth-991616a" rel="alternate"></link><updated>2010-07-14T10:16:00Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-14:/diabetes/glaxos-diabetes-drug-avandia-faces-moment-truth-991616a/</id><summary type="html">&lt;div&gt;&lt;p&gt;Diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; faces a moment of truth Wednesday, when a committee will decide whether to recommend pulling it from the market because it has been associated with increased heart problems.&lt;/p&gt;&lt;p&gt;The committee, convened at the request of the &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;Food and Drug Administration&lt;/a&gt;, began its work on Tuesday as two US senators said Avandia manufacturer &lt;a title=...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Philadelphia"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Western Europe"></category><category term="Avandia"></category><category term="Actos"></category><category term="Chuck Grassley"></category><category term="Max Baucus"></category><category term="Mary Anne Rhyne"></category><category term="Cardiovascular Medicine"></category><category term="Thomas Marciniak"></category></entry><entry><title>FDA Panel Seems Skeptical Over Key Avandia&amp;nbsp;Data</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-panel-skeptical-key-avandianbspdata-1308489a" rel="alternate"></link><updated>2010-09-10T13:39:14Z</updated><author><name>Health.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/fda-panel-skeptical-key-avandianbspdata-1308489a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="The New York Times Company"></category><category term="Food and Drug Administration"></category><category term="National Heart, Lung, and Blood Institute"></category><category term="GlaxoSmithKline plc"></category><category term="The New England Journal of Medicine"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Actos"></category><category term="American Association of Clinical Endocrinologists"></category><category term="The Endocrine Society"></category><category term="University of Newcastle upon Tyne"></category><category term="Cardiovascular Medicine"></category><category term="Ellis Unger"></category><category term="Thomas Marciniak"></category><category term="Ellen Strahlman"></category><category term="Nancy Geller"></category><category term="FDA's Center for Drug Control and Evaluation"></category><category term="Office of Biostatistics Research"></category></entry><entry><title>Glaxo covered up diabetes drug's risks: US lawmakers</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxo-covered-diabetes-drugs-risks-lawmakers-990710a" rel="alternate"></link><updated>2010-07-13T13:15:37Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-13:/diabetes/glaxo-covered-diabetes-drugs-risks-lawmakers-990710a/</id><summary type="html">&lt;div&gt;&lt;p&gt;British pharmaceutical giant &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt; hid the dangers of its top-selling diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; and secretly wrote scientific articles about it, two US lawmakers charged Tuesday.&lt;/p&gt;&lt;p&gt;The allegations came as the &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;Food and Drug Administration&lt;/a&gt; (FDA) opened a two-day meeting of expert...</summary><category term="Politics"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Hamburg"></category><category term="Chuck Grassley"></category><category term="Max Baucus"></category><category term="Margaret Hamburg"></category></entry><entry><title>Glaxo withheld info on diabetes drug's risks: US lawmakers</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxo-withheld-info-diabetes-drugs-risks-lawmakers-990565a" rel="alternate"></link><updated>2010-07-13T11:16:38Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-13:/diabetes/glaxo-withheld-info-diabetes-drugs-risks-lawmakers-990565a/</id><summary type="html">&lt;div&gt;&lt;p&gt;UK pharmaceutical giant &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt; kept the dangers of its top-selling diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; out of the public eye and ghostwrote scientific articles about it, US lawmakers charged Tuesday.&lt;/p&gt;&lt;p&gt;The allegations came as the &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;Food and Drug Administration&lt;/a&gt; (FDA) opened a two-day meeting...</summary><category term="Politics"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="The Wall Street Journal"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Hamburg"></category><category term="Chuck Grassley"></category><category term="Max Baucus"></category><category term="Margaret Hamburg"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Glaxo 'withheld info on diabetes drug's heart risks'</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxo-withheld-info-diabetes-drugs-heart-risks-990328a" rel="alternate"></link><updated>2010-07-13T08:16:32Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-13:/diabetes/glaxo-withheld-info-diabetes-drugs-heart-risks-990328a/</id><summary type="html">&lt;div&gt;&lt;p&gt;British pharmaceutical giant &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt; withheld from &lt;a title="United States" href="/topic/United+States" &gt;US&lt;/a&gt; drug safety regulators information about the possible dangers of top-selling diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, a report in the US press said Tuesday.&lt;/p&gt;&lt;p&gt;The allegation was made in the &lt;a title="The Wall Street Journal" href="/topic/The+Wall+Street+Journal" &gt;Wall S...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="The Wall Street Journal"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category></entry><entry><title>Glaxo withheld info on diabetes drug's heart risks: report</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxo-withheld-info-diabetes-drugs-heart-risks-report-990311a" rel="alternate"></link><updated>2010-07-13T08:15:52Z</updated><author><name>AFP American Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-13:/diabetes/glaxo-withheld-info-diabetes-drugs-heart-risks-report-990311a/</id><summary type="html">&lt;div&gt;&lt;p&gt;British pharmaceutical giant &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt; withheld from &lt;a title="United States" href="/topic/United+States" &gt;US&lt;/a&gt; drug safety regulators information about the possible dangers of top-selling diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, a report in the US press said Tuesday.&lt;/p&gt;&lt;p&gt;The allegation was made in the &lt;a title="The Wall Street Journal" href="/topic/The+Wall+Street+Journal" &gt;Wall S...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="The Wall Street Journal"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category></entry><entry><title>Avandia Heart Risks Buried by Drug Company: Report</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-heart-risks-buried-drug-company-report-1328406a" rel="alternate"></link><updated>2010-09-10T17:37:01Z</updated><author><name>EverydayHealth.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/avandia-heart-risks-buried-drug-company-report-1328406a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="New York City"></category><category term="The New York Times Company"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="Lenox Hill Hospital"></category><category term="Cardiovascular Medicine"></category><category term="Kirk Garratt"></category><category term="Thomas Marciniak"></category><category term="Ellen Strahlman"></category></entry><entry><title>U.S. meeting nears on risks of Glaxo diabetes drug</title><link href="http://diabetesinfoandtreatment.com/diabetes/meeting-nears-risks-glaxo-diabetes-drug-990016a" rel="alternate"></link><updated>2010-07-13T01:30:15Z</updated><author><name>Reuters US Online Report Top News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-13:/diabetes/meeting-nears-risks-glaxo-diabetes-drug-990016a/</id><summary type="html">&lt;div&gt;&lt;p&gt;WASHINGTON (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - A heated three-year safety debate about a &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline Plc&lt;/a&gt; diabetes pill reaches a climax this week as opponents and backers face off at a &lt;a title="United States" href="/topic/United+States" &gt;U.S.&lt;/a&gt; meeting that will help decide the drug's fate.&lt;/p&gt;&lt;p&gt;A panel of scientific experts meets later Tuesday and again Wednesday to co...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Actos"></category><category term="Reuters Group plc"></category><category term="Barack Obama"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category><category term="Thomas Marciniak"></category></entry><entry><title>History of Pregnancy-Linked Diabetes Helps Predict Its Return</title><link href="http://diabetesinfoandtreatment.com/gestational-diabetes/history-pregnancylinked-diabetes-helps-predict-return-1328351a" rel="alternate"></link><updated>2010-09-10T17:36:19Z</updated><author><name>EverydayHealth.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/gestational-diabetes/history-pregnancylinked-diabetes-helps-predict-return-1328351a/</id><summary type="html">...</summary><category term="Family"></category><category term="Pregnancy and Childbirth"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Gestational Diabetes"></category><category term="United States"></category><category term="California"></category><category term="Women's Health"></category><category term="Kaiser Permanente"></category><category term="Avandia"></category><category term="Prenatal Health, Labor and Delivery"></category><category term="American Journal of Obstetrics &amp; Gynecology"></category><category term="Darios Getahun"></category><category term="Results FDA"></category></entry><entry><title>FDA Reviewer Questions Results of Key Avandia Trial</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-reviewer-questions-results-key-avandia-trial-1335514a" rel="alternate"></link><updated>2010-09-10T20:05:00Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/fda-reviewer-questions-results-key-avandia-trial-1335514a/</id><summary type="html">...</summary><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="New York City"></category><category term="The New York Times Company"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="American Diabetes Association"></category><category term="University of Miami Leonard M. Miller School of Medicine"></category><category term="Avandia"></category><category term="Actos"></category><category term="The Associated Press"></category><category term="EMEA Committee for Medicinal Products for Human Use"></category><category term="Joshua Sharfstein"></category><category term="Lenox Hill Hospital"></category><category term="Cardiovascular Medicine"></category><category term="Kirk Garratt"></category><category term="Thomas Marciniak"></category><category term="Ellen Strahlman"></category></entry><entry><title>Diabetes drug Avandia gets new setback ahead of US decision</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-drug-avandia-new-setback-decision-987687a" rel="alternate"></link><updated>2010-07-09T14:15:51Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-09:/diabetes/diabetes-drug-avandia-new-setback-decision-987687a/</id><summary type="html">&lt;div&gt;&lt;p&gt;&lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s blockbuster diabetes treatment &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; suffered a new setback Friday when &lt;a title="United States" href="/topic/United+States" &gt;US&lt;/a&gt; health officials offered more evidence of the drug's increased link to heart problems.&lt;/p&gt;&lt;p&gt;A document released by the &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;Food and Drug Admin...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Thomas Marciniak"></category></entry><entry><title>FDA review spotlights heart risk of diabetes pill</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-review-spotlights-heart-risk-diabetes-pill-987317a" rel="alternate"></link><updated>2010-07-09T07:16:01Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-09:/diabetes/fda-review-spotlights-heart-risk-diabetes-pill-987317a/</id><summary type="html">&lt;div id="subtitle"&gt;FDA scrutinizes &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;'s safety risks ahead of meeting to decide fate of diabetes pill&lt;/div&gt;&lt;div&gt;&lt;p&gt;A review by federal health scientists reinforces potential ties between the diabetes pill Avandia and heart attack and death, opening the door for government action, including a possible withdrawal of the once blockbuster drug.&lt;/p&gt;&lt;p&gt;The &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;FDA&lt;/a&gt; post...</summary><category term="Consumer Protection"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Medicare"></category><category term="Japan"></category><category term="United Kingdom"></category><category term="Capitol Hill"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="IMS Health Inc."></category><category term="Western Europe"></category><category term="Avandia"></category><category term="Actos"></category><category term="East Asia"></category><category term="David Graham"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Cardiovascular Medicine"></category></entry><entry><title>European agency to review safety of GSK's Avandia</title><link href="http://diabetesinfoandtreatment.com/diabetes/european-agency-review-safety-gsks-avandia-987156a" rel="alternate"></link><updated>2010-07-09T03:30:13Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-09:/diabetes/european-agency-review-safety-gsks-avandia-987156a/</id><summary type="html">&lt;div id="subtitle"&gt;&lt;a title="European Medicines Agency" href="/topic/European+Medicines+Agency" &gt;European Medicines Agency&lt;/a&gt; to review safety of &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;p&gt;The European Medicines Agency says it will review the safety of the diabetes drug Avandia following research suggesting it is linked to a higher risk of heart problems, strokes and dea...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="EMEA Committee for Medicinal Products for Human Use"></category></entry><entry><title>EU agency probes safety of Glaxo's Avandia drug</title><link href="http://diabetesinfoandtreatment.com/diabetes/eu-agency-probes-safety-glaxos-avandia-drug-987115a" rel="alternate"></link><updated>2010-07-09T03:15:21Z</updated><author><name>Reuters US Online Report Business News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-09:/diabetes/eu-agency-probes-safety-glaxos-avandia-drug-987115a/</id><summary type="html">&lt;div&gt;&lt;p&gt;LONDON (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - European regulators are launching a new probe into the safety of &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline Plc&lt;/a&gt;'s diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt;, adding to pressure on a medicine that already faces a grilling from U.S. experts next week.&lt;/p&gt;&lt;p&gt;The &lt;a title="European Medicines Agency" href="/topic/European+Medicines+Agency" &gt;E...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="European Medicines Agency"></category><category term="Avandia"></category><category term="Avandamet"></category><category term="London"></category><category term="Reuters Group plc"></category><category term="EMEA Committee for Medicinal Products for Human Use"></category><category term="Ben Hirschler"></category><category term="Tony Hoos"></category></entry><entry><title>Knockout blow for diabetes drug Avandia?</title><link href="http://diabetesinfoandtreatment.com/diabetes/knockout-blow-diabetes-drug-avandia-1323138a" rel="alternate"></link><updated>2010-09-10T16:09:12Z</updated><author><name>Consumer Reports</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/diabetes/knockout-blow-diabetes-drug-avandia-1323138a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medicare"></category><category term="Food and Drug Administration"></category><category term="The Cleveland Clinic"></category><category term="Journal of the American Medical Association"></category><category term="Avandia"></category><category term="Actos"></category><category term="Best Buy Co. Inc."></category><category term="David Graham"></category><category term="Steven Nissen"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Fewer Dying From Type 1 Diabetes</title><link href="http://diabetesinfoandtreatment.com/type-1-diabetes/dying-type-1-diabetes-1328111a" rel="alternate"></link><updated>2010-09-10T17:31:25Z</updated><author><name>EverydayHealth.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/type-1-diabetes/dying-type-1-diabetes-1328111a/</id><summary type="html">...</summary><category term="Autoimmune Disorders"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 1 Diabetes"></category><category term="United States"></category><category term="Orlando (Florida)"></category><category term="University of Pittsburgh"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Allegheny County"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>New research links diabetes drug to heart ailments</title><link href="http://diabetesinfoandtreatment.com/diabetes/new-research-links-diabetes-drug-heart-ailments-977070a" rel="alternate"></link><updated>2010-06-28T13:16:14Z</updated><author><name>AFP Global Edition</name></author><id>tag:diabetesinfoandtreatment.com,2010-06-28:/diabetes/new-research-links-diabetes-drug-heart-ailments-977070a/</id><summary type="html">&lt;div&gt;&lt;p&gt;Patients taking the anti-diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; may be at increased risk of cardiovascular ailments compared to those taking other drugs to treat diabetes, a &lt;a title="United States" href="/topic/United+States" &gt;US&lt;/a&gt; government study found Monday.&lt;/p&gt;&lt;p&gt;The analysis by the &lt;a title="Food and Drug Administration" href="/topic/Food+and+Drug+Administration" &gt;US Food and Drug Administration&lt;/a&gt; was in line with a spate of recent studies which ha...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Diabetes Symptoms"></category><category term="Stroke"></category><category term="United States"></category><category term="Food and Drug Administration"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="Journal of the American Medical Association"></category><category term="University of Toronto"></category><category term="Avandia"></category><category term="Steven Nissen"></category><category term="Brain and Nerve Health"></category><category term="David Juurlink"></category><category term="Kathy Wolski"></category></entry><entry><title>Studies see heart risk with Glaxo diabetes drug</title><link href="http://diabetesinfoandtreatment.com/diabetes/studies-heart-risk-glaxo-diabetes-drug-976672a" rel="alternate"></link><updated>2010-06-28T07:15:27Z</updated><author><name>Reuters US Online Report Health News</name></author><id>tag:diabetesinfoandtreatment.com,2010-06-28:/diabetes/studies-heart-risk-glaxo-diabetes-drug-976672a/</id><summary type="html">&lt;div&gt;&lt;p&gt;WASHINGTON (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - Two studies released on Monday reported serious heart risks with &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline Plc&lt;/a&gt; diabetes pill &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; as U.S. regulators decide whether the drug should stay on the market.&lt;/p&gt;&lt;p&gt;An analysis of 56 clinical trials found Avandia increased the chances of a heart attack by 28 percent to...</summary><category term="Health Care Issues"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="Ohio"></category><category term="Medicaid"></category><category term="Medicare"></category><category term="United Kingdom"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="The Cleveland Clinic"></category><category term="GlaxoSmithKline plc"></category><category term="AstraZeneca Group"></category><category term="Journal of the American Medical Association"></category><category term="Toronto"></category><category term="Western Europe"></category><category term="Bristol-Myers Squibb Company"></category><category term="Avandia"></category><category term="Actos"></category><category term="Reuters Group plc"></category><category term="David Graham"></category><category term="Januvia"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Joshua Sharfstein"></category><category term="Steven Nissen"></category><category term="Institute for Clinical Evaluative Sciences"></category><category term="Paying for Health Care"></category><category term="Cardiovascular Medicine"></category><category term="Susan Heavey"></category><category term="Lisa Richwine"></category><category term="London (England)"></category><category term="New York Stock Exchange"></category><category term="David Juurlink"></category><category term="Onglyza"></category></entry><entry><title>Drug Combo Staves Off Type 2 Diabetes</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/drug-combo-staves-type-2-diabetes-1335311a" rel="alternate"></link><updated>2010-09-10T19:58:44Z</updated><author><name>HealthCentral.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-10:/type-2-diabetes/drug-combo-staves-type-2-diabetes-1335311a/</id><summary type="html">...</summary><category term="Weight Loss"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Prediabetes"></category><category term="Type 2 Diabetes"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="The Lancet"></category><category term="University of Toronto"></category><category term="American Diabetes Association"></category><category term="Mount Sinai Medical Center"></category><category term="Avandia"></category><category term="Bernard Zinman"></category><category term="Cardiovascular Medicine"></category><category term="Richard Bergenstal"></category><category term="Body Weight"></category><category term="Leadership Sinai Centre for Diabetes"></category></entry><entry><title>Half doses of diabetes drugs can prevent disease</title><link href="http://diabetesinfoandtreatment.com/prediabetes/doses-diabetes-drugs-prevent-disease-951911a" rel="alternate"></link><updated>2010-06-02T15:45:41Z</updated><author><name>Reuters US Online Report Science News</name></author><id>tag:diabetesinfoandtreatment.com,2010-06-02:/prediabetes/doses-diabetes-drugs-prevent-disease-951911a/</id><summary type="html">&lt;div&gt;&lt;p&gt;WASHINGTON (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - Low doses of &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; combined with metformin can prevent diabetes without causing the most common side-effects, Canadian doctors reported on Wednesday.&lt;/p&gt;&lt;p&gt;Taking half a dose of Glaxo's combination pill reduced by two-thirds the risk that patients would...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Prediabetes"></category><category term="Type 2 Diabetes"></category><category term="United States"></category><category term="University of Southern California"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="University of Toronto"></category><category term="Mount Sinai Medical Center"></category><category term="International Diabetes Federation"></category><category term="Avandia"></category><category term="Actos"></category><category term="Reuters Group plc"></category><category term="Bernard Zinman"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>U.S. group urges FDA to halt Glaxo's Avandia trial</title><link href="http://diabetesinfoandtreatment.com/diabetes/group-urges-fda-halt-glaxos-avandia-trial-930601a" rel="alternate"></link><updated>2010-05-11T11:30:28Z</updated><author><name>Reuters US Online Report Health News</name></author><id>tag:diabetesinfoandtreatment.com,2010-05-11:/diabetes/group-urges-fda-halt-glaxos-avandia-trial-930601a/</id><summary type="html">&lt;div&gt;&lt;p&gt;WASHINGTON (&lt;a title="Reuters Group plc" href="/topic/Reuters+Group+plc" &gt;Reuters&lt;/a&gt;) - An major trial of &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; puts patients at risk and should be stopped, a &lt;a title="United States" href="/topic/United+States" &gt;U.S.&lt;/a&gt; advocacy group said on Tuesday, calling on regulators to immediately halt the global study of the controversial &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline Plc&lt;/a&gt; diabetes drug.&lt;/p&gt;&lt;...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="United States"></category><category term="Europe"></category><category term="Food and Drug Administration"></category><category term="Asia"></category><category term="Institute of Medicine"></category><category term="GlaxoSmithKline plc"></category><category term="American Heart Association"></category><category term="Pakistan"></category><category term="Avandia"></category><category term="Actos"></category><category term="Reuters Group plc"></category><category term="South Asia"></category><category term="Public Citizen Foundation"></category><category term="Latvia"></category><category term="Margaret Hamburg"></category><category term="Karen Riley"></category><category term="Sidney Wolfe"></category><category term="Takeda Pharmaceutical Co. Ltd."></category><category term="Baltic Countries"></category><category term="Mary Anne Rhyne"></category><category term="Cardiovascular Medicine"></category><category term="Susan Heavey"></category><category term="Lisa Von Ahn"></category><category term="David Juurlink"></category></entry><entry><title>FDA Mulling End to Avandia-Actos Trial on Safety Worries</title><link href="http://diabetesinfoandtreatment.com/diabetes/fda-mulling-avandiaactos-trial-safety-worries-3194522a" rel="alternate"></link><updated>2010-10-25T14:38:49Z</updated><author><name>Wall Street Journal Health Blog</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/diabetes/fda-mulling-avandiaactos-trial-safety-worries-3194522a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Sciences"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Food and Drug Administration"></category><category term="Institute of Medicine"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="Joshua Sharfstein"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Avandia Drug Recall</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/avandia-drug-recall-1184411a" rel="alternate"></link><updated>2010-09-09T19:01:34Z</updated><author><name>ArticlesBase</name></author><id>tag:diabetesinfoandtreatment.com,2010-09-09:/type-2-diabetes/avandia-drug-recall-1184411a/</id><summary type="html">&lt;p&gt;Avandia is an oral diabetes medication that improves your body's blood sugar levels by making the cells in your body more receptive to insulin. Produced by GlaxoSmithKline, Avandia is an oral thiazolidinedione medication prescribed to treat type-2 diabetes, or adult onset diabetes. It can be used in combination with insulin and other medications for patients with this type of diabetes. Avandia is not indicated to treat type-1 or juvenile diabetes. &lt;strong&gt;Other Uses for Avandia&lt;/strong&gt; While...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Diabetes Symptoms"></category><category term="Hypoglycemia"></category><category term="Type 1 Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Medical Drug Therapy"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Avandia Researchers' Financial Ties Questioned</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-researchers-financial-ties-questioned-3151639a" rel="alternate"></link><updated>2010-10-25T11:34:46Z</updated><author><name>EverydayHealth.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/diabetes/avandia-researchers-financial-ties-questioned-3151639a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Food and Drug Administration"></category><category term="Centers for Disease Control and Prevention"></category><category term="Mayo Foundation for Medical Education and Research"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Byetta LARS: How the FDA's Analysis Paralysis May Aid Amylin</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/byetta-lars-fdas-analysis-paralysis-aid-amylin-3144343a" rel="alternate"></link><updated>2010-10-25T11:23:04Z</updated><author><name>SeekingAlpha</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/type-2-diabetes/byetta-lars-fdas-analysis-paralysis-aid-amylin-3144343a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Kidney Failure"></category><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Pancreatitis"></category><category term="Kidney and Urologic Health"></category><category term="Technology"></category><category term="Medical Technology"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="Food and Drug Administration"></category><category term="Eli Lilly and Company"></category><category term="Center for Drug Evaluation and Research"></category><category term="Janet Woodcock"></category><category term="GlaxoSmithKline plc"></category><category term="The New England Journal of Medicine"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Byetta"></category><category term="Novo Nordisk AS"></category><category term="Alkermes Inc."></category><category term="Amylin Pharmaceuticals Inc."></category><category term="Cardiovascular Medicine"></category><category term="Victoza"></category></entry><entry><title>Glaxo defends handling of Avandia heart risks</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxo-defends-handling-avandia-heart-risks-853970a" rel="alternate"></link><updated>2010-04-16T06:58:25Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-04-16:/diabetes/glaxo-defends-handling-avandia-heart-risks-853970a/</id><summary type="html">&lt;div id="subtitle"&gt;&lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;Glaxo&lt;/a&gt; fires back against Senate report, says it disclosed safety risks to FDA in 2005&lt;/div&gt;&lt;div&gt;&lt;p&gt;GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; "mischaracterizes and distorts" the company's record.&lt;/p&gt;&lt;p&gt;In a memo posted online, the British drugmaker takes aim at the highly critical &lt;a title...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Avandia and Heart Problems - Isn't It Time to Learn from the Vioxx Debacle?</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-heart-problems-isnt-time-learn-vioxx-debacle-3124046a" rel="alternate"></link><updated>2010-10-25T08:33:41Z</updated><author><name>About.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/diabetes/avandia-heart-problems-isnt-time-learn-vioxx-debacle-3124046a/</id><summary type="html">...</summary><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Medical Treatments and Procedures"></category><category term="Pain Management"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="The New York Times Company"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Vioxx"></category><category term="Cardiovascular Medicine"></category><category term="Merrill Goozner"></category></entry><entry><title>Avandia: What Should Patients Do?</title><link href="http://diabetesinfoandtreatment.com/diabetes/avandia-patients-3119206a" rel="alternate"></link><updated>2010-10-25T08:06:24Z</updated><author><name>Wall Street Journal Health Blog</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/diabetes/avandia-patients-3119206a/</id><summary type="html">...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="New York"></category><category term="Food and Drug Administration"></category><category term="Minneapolis"></category><category term="GlaxoSmithKline plc"></category><category term="Mount Sinai School of Medicine"></category><category term="American Diabetes Association"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category><category term="Richard Bergenstal"></category><category term="International Diabetes Center"></category><category term="Zachary Bloomgarden"></category></entry><entry><title>FDA Reviews Avandia Safety Data</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/fda-reviews-avandia-safety-data-3116154a" rel="alternate"></link><updated>2010-10-25T07:57:53Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/type-2-diabetes/fda-reviews-avandia-safety-data-3116154a/</id><summary type="html">...</summary><category term="Politics"></category><category term="U.S. Politics"></category><category term="World Politics"></category><category term="U.S. Congressional Politics"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category></entry><entry><title>Avandia (rosiglitazone): FDA reviewing a large, long-term clinical study on possible risks for cardiovascular outcomes with use of rosiglitazone</title><link href="http://diabetesinfoandtreatment.com/type-2-diabetes/avandia-rosiglitazone-fda-reviewing-large-longterm-clinical-study-risks-cardiovascular-outcomes-rosiglitazone-3116140a" rel="alternate"></link><updated>2010-10-25T07:57:53Z</updated><author><name>Drugs.com</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/type-2-diabetes/avandia-rosiglitazone-fda-reviewing-large-longterm-clinical-study-risks-cardiovascular-outcomes-rosiglitazone-3116140a/</id><summary type="html">...</summary><category term="Clinical Trials"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Type 2 Diabetes"></category><category term="Food and Drug Administration"></category><category term="Avandia"></category></entry><entry><title>Diabetes Rivals Lick Chops Over Avandia Setback</title><link href="http://diabetesinfoandtreatment.com/diabetes/diabetes-rivals-lick-chops-avandia-setback-3115906a" rel="alternate"></link><updated>2010-10-25T07:56:48Z</updated><author><name>Forbes</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-25:/diabetes/diabetes-rivals-lick-chops-avandia-setback-3115906a/</id><summary type="html">...</summary><category term="Cancer"></category><category term="Thyroid Cancer"></category><category term="Health Care Issues"></category><category term="Prescription Drugs"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="U.S. Senate"></category><category term="Washington, DC"></category><category term="U.S. Congress"></category><category term="Food and Drug Administration"></category><category term="Eli Lilly and Company"></category><category term="Pennsylvania"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Actos"></category><category term="H.L. Mencken"></category><category term="U.S. Senate Committee on Finance"></category><category term="Byetta"></category><category term="Novo Nordisk AS"></category><category term="Chuck Grassley"></category><category term="Max Baucus"></category><category term="Amylin Pharmaceuticals Inc."></category><category term="Edmund Burke"></category><category term="David Kliff"></category><category term="Victoza"></category><category term="Boies Penrose"></category></entry><entry><title>Glaxo a Buy Despite Avandia Scare</title><link href="http://diabetesinfoandtreatment.com/diabetes/glaxo-buy-avandia-scare-3418428a" rel="alternate"></link><updated>2010-10-27T07:41:58Z</updated><author><name>Barron's</name></author><id>tag:diabetesinfoandtreatment.com,2010-10-27:/diabetes/glaxo-buy-avandia-scare-3418428a/</id><summary type="html">...</summary><category term="Financial Markets"></category><category term="American Depositary Receipts"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="The New York Times Company"></category><category term="Food and Drug Administration"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="U.S. Senate Committee on Finance"></category></entry><entry><title>Diabetes Drug Safety Study</title><link href="http://diabetesinfoandtreatment.com/photo/diabetes-drug-safety-study-2319874p" rel="alternate"></link><updated>2010-07-21T10:17:40Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-21:/photo/diabetes-drug-safety-study-2319874p/</id><summary type="html">FILE - In this June 30, 2010 file photo, a pharmacist holds a bottle of &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; pills at Maximart Pharmacy in &lt;a title="Palo Alto" href="/topic/Palo+Alto" &gt;Palo Alto&lt;/a&gt;, &lt;a title="California" href="/topic/California" &gt;Calif.&lt;/a&gt; Federal health officials say new patients should not be enrolled in a study of &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s controversial diabetes pill Avandia, after experts last w...</summary><category term="Politics"></category><category term="Political Policy"></category><category term="Domestic Policy"></category><category term="Social Policy"></category><category term="Public Health Policy"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="California"></category><category term="Palo Alto"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry><entry><title>Diabetes Pill FDA</title><link href="http://diabetesinfoandtreatment.com/photo/diabetes-pill-fda-2316513p" rel="alternate"></link><updated>2010-07-13T14:16:35Z</updated><author><name>AP News</name></author><id>tag:diabetesinfoandtreatment.com,2010-07-13:/photo/diabetes-pill-fda-2316513p/</id><summary type="html">FILE - In this June 30, 2010 file photo, a pharmacist holds a bottle of &lt;a title="Avandia" href="/topic/Avandia" &gt;Avandia&lt;/a&gt; pills at Maximart Pharmacy in &lt;a title="Palo Alto" href="/topic/Palo+Alto" &gt;Palo Alto&lt;/a&gt;, &lt;a title="California" href="/topic/California" &gt;Calif.&lt;/a&gt; Federal health advisers discuss whether &lt;a title="GlaxoSmithKline plc" href="/topic/GlaxoSmithKline+plc" &gt;GlaxoSmithKline&lt;/a&gt;'s diabetes pill Avandia should be pulled from the market. The one-time-blockbuster drug's sales ha...</summary><category term="Heart Attacks"></category><category term="Internal Medicine"></category><category term="Metabolic Disorders"></category><category term="Diabetes"></category><category term="Biotechnology Sector"></category><category term="Pharmaceuticals Sector"></category><category term="United States"></category><category term="California"></category><category term="Palo Alto"></category><category term="GlaxoSmithKline plc"></category><category term="Avandia"></category><category term="Cardiovascular Medicine"></category></entry></feed>
